source
- Boulevard Bio launches with $65 million to develop bispecific antibodies for IgA nephropathy and other autoimmune diseasesBoulevard Bio, a new biotech co-founded by autoimmune researcher Georg Schett and former Sanofi CSO Frank Nestle, announced its launch on Wednesday with $65 million in funding. The company’s first…
- AI-focused biotech firms drive biopharma toward a 'fail-fast' drug development modelAI is quickly becoming a central force in drug development as tech capital pours into biopharma, reshaping how new medicines are discovered. Tyrone Lam, chief business officer at GATC Health, says…